Jetrea is new non-surgical eye treatment

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, prepares Diane Keene of Naples for a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, examines the eye of Diane Keene's before administering a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, goes over the chart of Diane Keene's eye in order to administer a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, prepares Diane Keene of Naples for a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, left, director of Retina Health Center, and Clinical Trials Contract Manager Adam Sgarlata open a package of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, prepares a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, consults with Diane Keene of Naples before administering a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, prepares a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, consults with Diane Keene of Naples before administering a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, examines Diane Keene of Naples after a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, consults with Diane Keene of Naples before administering a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Diane Keene of Naples leaves the Retina Center in Fort Myers with her husband, Irving, after she received a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, examines Diane Keene of Naples after a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.

Special to the Daily News/Jason Easterly Dr. Alexander M. Eaton, director of Retina Health Center, examines Diane Keene of Naples after a dose of Jetrea, a new non-surgical treatment option for patients with symptomatic vitreomacular adhesion, VMA, at Retina Health Center in Fort Myers on Tuesday morning. Jetrea is an enzyme that breaks down the proteins in the eye responsible for VMA, a progressive and debilitating eye disease. The treatment has just recently been approved by the Food and Drug Administration.